Niclosamide inhibition of STAT3 synergizes with erlotinib in human colon cancer

Niclosamide inhibition of STAT3 synergizes with erlotinib in human colon cancer

Lingyi Shi,1,* Hailun Zheng,1,* Wanle Hu,2 Bin Zhou,2 Xuanxuan Dai,3 Yi Zhang,3 Zhiguo Liu,1 Xiaoping Wu,1 Chengguang Zhao,1 Guang Liang1 1Chemical Biology Research Center, School of Pharmaceutical Sciences, 2Department of Coloproctology, The Second Affiliated Hospital and Yuying Children&rsquo...

Full description

Bibliographic Details
Main Authors:	Shi L, Zheng H, Hu W, Zhou B, Dai X, Zhang Y, Liu Z, Wu X, Zhao C, Liang G
Format:	Article
Language:	English
Published:	Dove Medical Press 2017-03-01
Series:	OncoTargets and Therapy
Subjects:	STAT3 EGFR Erlotinib Niclosamide Colon cancer
Online Access:	https://www.dovepress.com/niclosamide-inhibition-of-stat3-synergizes-with-erlotinib-in-human-col-peer-reviewed-article-OTT

Similar Items

A rapid and convenient method for synthesis of anilinoquinazoline: an improved synthesis of erlotinib derivatives
by: Zahra Haghighijoo, et al.
Published: (2015-09-01)

Niclosamide, an antihelmintic drug, enhances efficacy of PD-1/PD-L1 immune checkpoint blockade in non-small cell lung cancer
by: Fan Luo, et al.
Published: (2019-09-01)

Niclosamide and its derivative DK‐520 inhibit RANKL‐induced osteoclastogenesis
by: Yurui Jiao, et al.
Published: (2020-08-01)

Effects of Erlotinib on 34 Patients with Advanced Squamous Cell Lung Cancer
by: Fang CHENG, et al.
Published: (2016-10-01)

Erlotinib in combined therapy of common lung adenocarcinoma in the presence of EGFR gene mutation
by: S. V. Orlov, et al.
Published: (2019-06-01)

Combined use of anti-ErbB monoclonal antibodies and erlotinib enhances antibody-dependent cellular cytotoxicity of wild-type erlotinib-sensitive NSCLC cell lines
by: Cavazzoni Andrea, et al.
Published: (2012-12-01)

Indirect Spectrophotometric Determination of Niclosamide in Pharmaceutical Preparations
by: Nabeel S. Othman, et al.
Published: (2018-06-01)

Niclosamide suppresses the expansion of follicular helper T cells and alleviates disease severity in two murine models of lupus via STAT3
by: Se Gwang Jang, et al.
Published: (2021-02-01)

Low doses of niclosamide and quinacrine combination yields synergistic effect in melanoma via activating autophagy-mediated p53-dependent apoptosis
by: Ding, C., et al.
Published: (2022)

Inhibition of STAT3 by niclosamide synergizes with erlotinib against head and neck cancer.
by: Rui Li, et al.
Published: (2013-01-01)

HCC-derived EGFR mutants are functioning, EGF-dependent, and erlotinib-resistant
by: Natthaporn Sueangoen, et al.
Published: (2020-03-01)

Central nervous system progression in advanced non–small cell lung cancer patients with EGFR mutations in response to first-line treatment with two EGFR-TKIs, gefitinib and erlotinib: a comparative study
by: Meng-Xia Li, et al.
Published: (2017-04-01)

Role of Erlotinib 100 mg/d in the Treatment of  Advanced Adenocarcinoma Lung Cancer Failed to Previous Chemotherapy
by: Chunlei SHI, et al.
Published: (2011-06-01)

Niclosamide ethanolamine ameliorates diabetes-related muscle wasting by inhibiting autophagy
by: Yuchun Cai, et al.
Published: (2021-06-01)

Inhibition of human immunodeficiency virus type 1 by niclosamide through mTORC1 inhibition
by: Nattamon Niyomdecha, et al.
Published: (2020-06-01)

Niclosamide Exhibits Potent Anticancer Activity and Synergizes with Sorafenib in Human Renal Cell Cancer Cells
by: Xinyi Yu, et al.
Published: (2018-05-01)

Pooled Analysis of the Trials of Erlotinib Monotherapy for Epidermal Growth Factor Receptor (EGFR)-mutant Advanced Non-small Cell Lung Cancer
by: Li MA, et al.
Published: (2009-12-01)

Efficacy of niclosamide as a potential antipenetrant (TAP) against cercariae of Schistosoma mansoni monkeys
by: John I. Bruce, et al.
Published: (1992-01-01)

<b>Electrochemical oxidation of niclosamide at a glassy carbon electrode and its determination by voltammetry</b>
by: Hailemichael Alemu, et al.
Published: (2003-06-01)

Suppression of c-MET overcomes erlotinib resistance in tongue cancer cells
by: Huang K, et al.
Published: (2018-09-01)

Sensitivity of Oncomelania hupensis to Niclosamide: A Nation-Wide Survey in China
by: Jianrong Dai, et al.
Published: (2014-03-01)

Gene Mutation Analysis in EGFR Wild Type NSCLC Responsive to Erlotinib: Are There Features to Guide Patient Selection?
by: Paola Ulivi, et al.
Published: (2014-12-01)

Metformin and Niclosamide Synergistically Suppress Wnt and YAP in APC-Mutated Colorectal Cancer
by: Hee Eun Kang, et al.
Published: (2021-07-01)

Niclosamide and Pyrvinium Are Both Potential Therapeutics for Osteosarcoma, Inhibiting Wnt–Axin2–Snail Cascade
by: Young Yi, et al.
Published: (2021-09-01)

Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Erlotinib Induces Dry Skin via Decreased in Aquaporin-3 Expression
by: Nobutomo Ikarashi, et al.
Published: (2020-04-01)

Niclosamide Blocks Rice Leaf Blight by Inhibiting Biofilm Formation of Xanthomonas oryzae
by: Sunil Kumar Sahu, et al.
Published: (2018-03-01)

Type I Collagen Aging Increases Expression and Activation of EGFR and Induces Resistance to Erlotinib in Lung Carcinoma in 3D Matrix Model
by: Thomas Sarazin, et al.
Published: (2020-09-01)

Comparison of erlotinib and pemetrexed as second-/third-line treatment for lung adenocarcinoma patients with asymptomatic brain metastases
by: He YY, et al.
Published: (2016-04-01)

Long-term effect of niclosamide on inhibition of bacterial leaf blight in rice
by: Kim Sung-Il, et al.
Published: (2016-12-01)

Dual Targeting EGFR and STAT3 With Erlotinib and Alantolactone Co-Loaded PLGA Nanoparticles for Pancreatic Cancer Treatment
by: Shihui Bao, et al.
Published: (2021-03-01)

Rhein shows potent efficacy against non-small-cell lung cancer through inhibiting the STAT3 pathway
by: Yang L, et al.
Published: (2019-02-01)

Niclosamide Triggers Non-Canonical LC3 Lipidation
by: Yajun Liu, et al.
Published: (2019-03-01)

Promising Combination Therapy with Bevacizumab and Erlotinib in an EGFR-Mutated NSCLC Patient with MET Amplification Who Showed Intrinsic Resistance to Initial EGFR-TKI Therapy
by: Nobuhiko Seki, et al.
Published: (2019-01-01)

Binding interactions of niclosamide with serum proteins
by: Esra Maltas
Published: (2014-12-01)

EGFR Promotes the Development of Triple Negative Breast Cancer Through JAK/STAT3 Signaling
by: Song X, et al.
Published: (2020-01-01)

Repurposing Niclosamide for Targeting Pancreatic Cancer by Inhibiting Hh/Gli Non-Canonical Axis of Gsk3β
by: Jyoti B. Kaushal, et al.
Published: (2021-06-01)

Durable complete remission of poor performance status metastatic lung adenocarcinoma patient treated with second-line erlotinib: a case report
by: Jovanovic D, et al.
Published: (2017-09-01)

Hydrotalcite–Niclosamide Nanohybrid as Oral Formulation towards SARS-CoV-2 Viral Infections
by: Goeun Choi, et al.
Published: (2021-05-01)

Dramatic Response to Teriprilumab and Anlotinib Combination Therapy in a patient with EGFR-Mutant Lung Adenocarcinoma Who Experienced Small-Cell Transformation−Mediated Erlotinib Resistance After Failure of Chemotherapy
by: Yuling Zhou, MS, et al.
Published: (2020-06-01)

Bovine Serum Albumin-Coated Niclosamide-Zein Nanoparticles as Potential Injectable Medicine against COVID-19
by: Sanoj Rejinold N, et al.
Published: (2021-07-01)

Cannot write session to /tmp/vufind_sessions/sess_96lkpao0lj6oms2du6f127h5b8